Atlas Trials

A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.

Clinical trial NCT07660172 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07660172
Sponsor
Novartis Pharmaceuticals
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Immune Thrombocytopenia (ITP)
Start date
2027-02-08
Primary completion
2033-04-22
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.